LCB-36

N/A

Report date: 2025/01/16 12:04:57

First In Class

Base Information

Drug NameLCB-36

Drug Alias NameLCB-36ALCB-36

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-CD20Anti-CD22

TargetsB-lymphocyte antigen CD20CD22

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLegochem Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesLegochem Biosciences Inc

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A